EX-99.1 7 ea030290601ex99-1.htm INFORMATION STATEMENT OF BIOKEY (CAYMAN), INC., DATED AUGUST [ ], 2026 Exhibit 99.1 INFORMATION STATEMENT BioKey (Cayman), Inc. Ordinary Shares (par value $0.0001 per share) This information statement has been prepared in connection with the spin-off by ABVC BioPharma, Inc. (“ ABVC ”) of its wholly owned subsidiary, BioKey (Cayman), Inc. (the “ Company,” “ SpinCo,” or “ BioKey Cayman ”). To effect the spin-off, ABVC distributed that number of the Company’s ordinary shares, par value $0.0001 (the “ Ordinary Shares ”) that it owns, which represents approximately 15% of the Company (the “ Distribution ”), on a pro rata basis to the holders of ABVC common stock, par value $0.0001 per share (the “ ABVC Common Stock ”). You should consult your own tax advisor as to the tax consequences of the Distribution to you, including potential tax consequences under state, local, and non-U.S. tax laws. If you are a record holder of ABVC Common Stock as of the close of business on July 24, 2026, which is the record date for the Distribution (the “Record Date”), you received your pro rata portion of 15% of BioKey Cayman’s issued and outstanding Ordinary Share…
Open exhibit ↗Current Report · Items 1.01, 7.01, 9.01 · 8-K
BioKey (Cayman), Inc.
Entry into a Material Definitive Agreement · Regulation FD Disclosure
Item 1.01 Entry into a Material Definitive Agreement BioKey (Cayman), Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Company”), previously filed with the U.S.…
Press release in this filing
INFORMATION STATEMENT →Disclosure sections
Item 1.01Item 1.01 - Entry into Material Agreement
Item
1.01 Entry into a Material Definitive Agreement
BioKey (Cayman), Inc.,
an exempted company incorporated with limited liability under the laws of the Cayman Islands (the “Company”), previously
filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form 10 (as amended,
the “Registration Statement”), relating to the separation (the “Spin-Off”) of the Company from
ABVC BioPharma, Inc. (“ABVC”), effected by ABVC’s distribution of approximately 15% of the issued and outstanding
ordinary shares, par value $0.0001 per share (“Ordinary Shares”), of the Company to holders of common stock of ABVC (the
“ABVC Common Stockholders”) as a pro rata dividend in the Spin-Off (the “Distribution”), pursuant to the
terms of that certain Separation and Distribution Agreement, dated as of June 22, 2026, between the Company and ABVC (the “Separation
Agreement”).
The Registration Statement
was declared effective by the SEC. The Registration Statement includes a preliminary information statement that describes the Spin-Off
and provides important information regarding the Company’s business and management. The final information statement, dated August
[ ], 2026 (the “Information Statement”), is attached hereto as Exhibit 99.1.
As further described in the Information Statement, the Spin-Off became
effective as of 11:59 p.m., New York City time, on August 21, 2026 (the “Distribution Date”). The ABVC Common Stockholders
received 0.169464 of an Ordinary Share for each share of ABVC common stock held at the close of business on July 24, 2026 (the “Record
Date”). ABVC distributed 4,500,390 Ordinary Shares to ABVC Common Stockholders. Following the Distribution, ABVC Common
Stockholders collectively maintain a 15% ownership in BioKey Cayman’s issued and outstanding Ordinary Shares and ABVC remains our
controlling shareholder, holding approximately 85% of BioKey Cayman’s issued and outstanding Ordinary Shares. All ownership percentages
included herein are based on the number of Ordinary Shares issued and outstanding as of August 21, 2026.
No trading market for
the Ordinary Shares currently exists. The Company intends to apply to have its Ordinary Shares quoted on the OTC Markets. Because the
Company is not currently listed on the OTC Markets, it has not yet been assigned a trading symbol. A trading symbol will be assigned in
connection with, and upon completion of, the OTC listing process.
In connection with the Spin-Off, on the Distribution Date, the Company
and ABVC entered into several agreements that, among other things, govern the ongoing relationship between the Company and ABVC following
the Spin-Off, including the Separation A, the Transitional Services Agreement, dated as of June 22, 2026 (the “TSA”),
the Tax Matters Agreement, dated as of June 22, 2026 (the “Tax Matters Agreement”), and the Employee Matters Agreement,
dated as of June 22, 2026 (the “Employee Matters Agreement”).
The Separation Agreement includes various post-closing
covenants, including agreements relating to the parties’ insurance policies, information sharing and other operational matters.
The Separation Agreement also includes a mutual release by the Company, on the one hand, and ABVC, on the other hand, of the other party
from certain specified liabilities, as well as mutual indemnification covenants pursuant to which the Company and ABVC have agreed to
indemnify each other from certain specified liabilities.
A summary of the material terms of the Separation Agreement is set
forth under the caption “Certain Relationships and Related Party Transactions - Agreements with ABVC - Separation and
Distribution Agreement” in the Information Statement and is incorporated by reference herein. The respective descriptions of the
Separation Agreement contained in this Current Report and the Information Statement do not purport to be complete and are qualified in
their entirety by reference to the full text of the Separation and Distribution Agreement, which is attached as Exhibit 2.1 to this Current
Report and incorporated by reference herein.
The foregoing descriptions of the TSA, the Tax Matters Agreement and
the Employee Matters Agreement do not purport to be complete and are qualified in their entirety by reference to the full text of such
agreements, copies of which are filed as Exhibits 10.1, 10.2 and 10.3, respectively, to this Current Report on Form 8-K and are incorporated
herein by reference.
Item 7.01.
Regulation FD Disclosure.
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 7.01.
The information furnished
pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that Section,
and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended,
or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.